Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Recruiting
Phase 2
Phase 3
Interventional Study
Chronic Spontaneous Urticaria (CSU)
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 344 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1\. Men and women aged 18 to 75 years.
* 2\. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines.
* 3\. CSU duration for ≥ 6 months prior to randomization.
* 4\. Before initiating any screening or study-specific procedures, the subject must voluntar…
Contacts